Experimental vaccine plus chemo aims to shrink HPV throat tumors and reduce radiation

NCT ID NCT05108870

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two experimental vaccines (HB-201 and HB-202) given with standard chemotherapy drugs (carboplatin and paclitaxel) to people with HPV16-positive oropharyngeal cancer. The goal is to see if this combination can shrink tumors enough to allow less intensive follow-up treatment, such as robotic surgery or lower doses of radiation and chemo. About 35 participants will be followed for two years to assess safety and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HB-201 and HB-202 (TheraT® vectors) plus carboplatin and paclitaxel chemotherapy
What this could lead to
If successful, this approach could shrink tumors more effectively and allow some patients to avoid high-dose radiation or extensive surgery, reducing long-term side effects.
What could go wrong
This is an early-phase trial with only 35 participants, so results may not apply broadly. The experimental vaccines are not yet FDA-approved, and side effects from combining them with chemotherapy are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Chicago

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.